CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives $8.36 Average PT from Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.3571.

A number of research analysts recently issued reports on the stock. Leerink Partners raised their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Rodman & Renshaw initiated coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th. Finally, Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th.

CAMP4 Therapeutics Trading Up 7.1%

CAMP stock opened at $4.20 on Monday. The stock has a market capitalization of $218.11 million, a P/E ratio of -1.78 and a beta of 0.08. CAMP4 Therapeutics has a 12 month low of $1.32 and a 12 month high of $7.75. The firm has a 50-day moving average price of $4.28 and a 200-day moving average price of $4.73.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The business had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, equities analysts predict that CAMP4 Therapeutics will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. EcoR1 Capital LLC acquired a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $1,992,000. Bridgeway Capital Management LLC acquired a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $36,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $61,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.